About Trinity Biotech plc
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic Substances
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TRIB
- Previous Close: $6.23
- 50 Day Moving Average: $6.56
- 200 Day Moving Average: $8.45
- 52-Week Range: $22,797,000.00 - $5.76
- Trailing P/E Ratio: 47.52
- Foreward P/E Ratio: 15.80
- P/E Growth: -0.17
- Market Cap: $144.08M
- Outstanding Shares: 22,797,000
- Beta: 1.17
- Net Margins: 3.04%
- Return on Equity: 2.73%
- Return on Assets: 1.60%
Companies Related to Trinity Biotech plc:
- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 7.27%
- Quick Ratio: 5.35%
What is Trinity Biotech plc's stock symbol?
Trinity Biotech plc trades on the NASDAQ under the ticker symbol "TRIB."
When will Trinity Biotech plc announce their earnings?
Trinity Biotech plc is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Trinity Biotech plc stock?
Trinity Biotech plc's stock is owned by many different of institutional and retail investors. Top institutional investors include Janus Capital Management LLC (6.23%), First Wilshire Securities Management Inc. (3.88%), Stonehill Capital Management LLC (3.24%), Stonepine Capital Management LLC (1.91%), Russell Investments Group Ltd. (1.83%) and Hunter Associates Investment Management LLC (1.83%).
Who sold Trinity Biotech plc stock? Who is selling Trinity Biotech plc stock?
Trinity Biotech plc's stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Renaissance Technologies LLC and Janus Capital Management LLC.
Who bought Trinity Biotech plc stock? Who is buying Trinity Biotech plc stock?
Trinity Biotech plc's stock was purchased by a variety of institutional investors in the last quarter, including First Wilshire Securities Management Inc., Stonehill Capital Management LLC, Stonepine Capital Management LLC, Russell Investments Group Ltd., Two Sigma Investments LP, ARS Investment Partners LLC, Oxford Asset Management and Hunter Associates Investment Management LLC.
How do I buy Trinity Biotech plc stock?
Shares of Trinity Biotech plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Trinity Biotech plc stock cost?
One share of Trinity Biotech plc stock can currently be purchased for approximately $6.32.